The Facts
What the science says about psychedelic-assisted therapy.
Significant Reduction in Depression
In a landmark Johns Hopkins study, 71% of participants with major depressive disorder showed significant reductions in symptoms after psilocybin-assisted therapy. 54% were in remission after treatment.
Lasting Reduction in Anxiety
A New York University study of patients with cancer-related anxiety found that 71% showed clinically significant reductions in anxiety and depression six months after a single guided psilocybin session.
Breakthrough Therapy Designation
The FDA has granted psilocybin Breakthrough Therapy designation for treatment-resistant depression and major depressive disorder — a recognition reserved for treatments that show substantial improvement over existing options.
Years of Human Use
Psychedelic plants have been used ceremonially and medicinally by indigenous cultures for thousands of years. Modern clinical research is now validating what many traditions have long understood about their healing potential.
Active Clinical Trials
There are currently more than 100 active clinical trials worldwide studying psilocybin, MDMA, and other psychedelics for conditions including PTSD, addiction, OCD, and end-of-life distress.
Oregon's Safety Record
Oregon became the first U.S. state to legalize regulated psilocybin services under Measure 109, passed in 2020 and launched in 2023. The program is overseen by the Oregon Health Authority and requires rigorous training, licensing, and compliance standards for all facilitators and service centers.
All services at Bentley Psychedelic Services are provided under Oregon Psilocybin Services (OPS) and comply fully with Oregon Health Authority guidelines. Psilocybin services are not therapy and are not a substitute for mental health treatment.
Psilocybin assisted therapy isn't for everyone and isn't a miracle cure. Your journey is just the beginning. Transformation comes with what you do next.
Get in Touch